Vimarsana
Biggest News Aggregation in the World

Page 12 - Guidelines Panel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Guidelines Panel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Guidelines Panel Today - Breaking & Trending Today

These people deserve the credit for the deaths of nearly a million Americans - Vimarsana News

These people deserve the credit for the deaths of nearly a million Americans

The best uncensored news, information, and analysis.

New Research in JNCCN Measures Drop in Cancer Detection Due to the COVID-19 Pandemic - Vimarsana News

New Research in JNCCN Measures Drop in Cancer Detection Due to the COVID-19 Pandemic

Study out of Ontario, Canada, finds an immediate diagnosis decrease of 34% in March 2020, followed by a slow and incomplete recovery

FOXNEWS The Faulkner Focus January 11, 2022 16:29:00 - Vimarsana News

FOXNEWS The Faulkner Focus January 11, 2022 16:29:00

Studies called active. there are six of those. that stands for accelerating covid-19 therapeutic interventions and vaccines. the whole gamut of direct anti-virals and monoclonal antibodies. as i mentioned anti-virals like paxlovid and others, the trials were done by the nih. in direct answer to how we know what to use, the nih has put together a guidelines panel made up of 48 highly-qualified clinicians and individuals with experience in covid-19 to give a prioritization of what you do if you are infected and with advanced disease in the hospital as well as what you do as an outpatient.

Ivermectin And Other COVID Drugs Condemned - Vimarsana News

Ivermectin And Other COVID Drugs Condemned

Avoid ivemectin, even if accessible through telemedicine. Read more on this condemned COVID treatment here and other unproven COVID drugs.

Merck to Deliver 3.1 Million Treatment Courses of COVID Antiviral - Vimarsana News

Merck to Deliver 3.1 Million Treatment Courses of COVID Antiviral

In June, the US government agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and in November agreed to buy an additional 1.4 billion courses for $1 billion.